Background
Methods
Databases
Primary myeloma cells
Statistical analysis
Results and discussion
Tumor suppressor functions of SULF1
SULF2, a protumorigenic endosulfatase
HM cohort (OS) | |||
---|---|---|---|
Pronostic variable | Proportional hazard ratio | P-value | |
Univariate Cox analysis | SULF2 ISS | 4.08 1.73 |
0.007
0.001
|
Multivariate Cox analysis | SULF2 ISS | 3.65 1.70 |
0.028
0.001
|
Univariate Cox analysis | SULF2 b2M Alb | 4.08 1.10 1.60 |
0.007
0.0001
0.04
|
Multivariate Cox analysis | SULF2 b2M Alb | 3.49 1.10 1.35 |
0.03
0.0001
0.24
|
Univariate Cox analysis | SULF2 HRS | 4.08 2.30 |
0.007
0.002
|
Multivariate Cox analysis | SULF2 HRS | 4.11 2.31 |
0.01
0.002
|
Univariate Cox analysis | SULF2 MS group | 4.08 2.14 |
0.007
0.001
|
Multivariate Cox analysis | SULF2 MS group | 3.84 1.97 |
0.023
0.028
|
Univariate Cox analysis | SULF2 IFM score | 4.08 3.09 |
0.007
0.0001
|
Multivariate Cox analysis | SULF2 IFM score | 4.29 3.22 |
0.014
0.0001
|
Univariate Cox analysis | SULF2 GPI | 4.08 2.21 |
0.007
0.0001
|
Multivariate Cox analysis | SULF2 GPI | 4.47 2.25 |
0.011
0.0001
|
Univariate Cox analysis | SULF2 MYEOV | 4.08 3.16 |
0.007
0.05
|
Multivariate Cox analysis | SULF2 MYEOV | 3.71 2.76 |
0.026
0.08
|
Univariate Cox analysis | SULF2 CD200 | 4.08 2.05 |
0.007
0.03
|
Multivariate Cox analysis | SULF2 CD200 | 3.86 1.03 |
0.02
0.05
|
Challenging observations concerning SULF1 and SULF2 in cancer
Gene overexpressed in cancer samples in comparison to their normal tissue counterpart | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cancer sample type | Datasets | SULF1 | SULF2 | Syndecan 1-4 | Glypican 1-6 | CD44 isoforms containing the alternatively spliced exon v3 | Agrin | Betaglycan | Perlecan | Serglycin | Testican 1-3 |
Leukemia | 33 |
Yes
| No | No | No | No | No | No |
Yes
|
Yes
|
Yes
|
Adrenal cancer | 2 |
Yes
| No | No | No | No | No | No | No | No | No |
Brain cancer | 23 |
Yes
|
Yes
|
Yes
|
Yes
|
Yes
|
Yes
|
Yes
|
Yes
|
Yes
| No |
Breast cancer | 44 |
Yes
|
Yes
|
Yes
| No |
Yes
| No | No | No | No |
Yes
|
Colon cancer | 12 |
Yes
| No | No | No |
Yes
| No | No | No | No | No |
Esophageal cancer | 4 |
Yes
| No |
Yes
|
Yes
|
Yes
|
Yes
|
Yes
|
Yes
|
Yes
| No |
Gastric cancer | 5 |
Yes
| No | No | No | No | No | No |
Yes
| No |
Yes
|
Head & Neck cancer | 5 |
Yes
|
Yes
|
Yes
|
Yes
|
Yes
| No | No |
Yes
|
Yes
| No |
Liver cancer | 4 | No |
Yes
| No | No | No | No | No | No | No | No |
Lung cancer | 16 |
Yes
| No | No | No | No |
Yes
| No | No | No |
Yes
|
Mesothelioma | 3 |
Yes
| No | No | No | No | No | No | No | No | No |
Pancreatic cancer | 6 |
Yes
| No |
Yes
| No | No | No | No |
Yes
|
Yes
|
Yes
|
Renal | 11 |
Yes
|
Yes
| No | No |
Yes
|
Yes
| No |
Yes
| No | No |
Sarcoma | 11 |
Yes
| No | No | No | No | No | No | No | No | No |
Skin cancer | 1 |
Yes
|
Yes
| No | No | No | No | No | No | No | No |
Testicular cancer | 1 |
Yes
|
Yes
|
Yes
|
Yes
| No |
Yes
| No | No |
Yes
| No |